Rigel Pharmaceuticals RIGL Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$45.97 down $1.28, 2.71% at close Oct 16
Last close · Previous close $47.25
- Market cap
- At the Oct 16 close
- P/E ratio
- 2.72On last 12 months’ EPS
- Diluted EPS
- $16.88Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$45.97down $1.28, 2.71%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$47.25Oct 15
- Volume141.43KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume236.78KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $24.95 to $52.24; now $45.97
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RIGL beat the S&P 500 in 4 of 7 periods.
| Period | RIGL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RIGL: up 3.3% S&P 500: up 1.5% | RIGL beat the S&P 500 by 1.8 percentage points Beat |
| 3M | RIGL: up 10.3% S&P 500: up 1.9% | RIGL beat the S&P 500 by 8.4 percentage points Beat |
| YTD | RIGL: up 7.3% S&P 500: up 12.8% | RIGL trailed the S&P 500 by 5.5 percentage points Trailed |
| 1Y | RIGL: up 63.5% S&P 500: up 16.8% | RIGL beat the S&P 500 by 46.7 percentage points Beat |
| Long term | ||
| 3Y | RIGL: up 375.6% S&P 500: up 81.5% +68.2% vs +22.0% a year | RIGL beat the S&P 500 by 294.1 percentage points Beat |
| 5Y | RIGL: up 36.0% S&P 500: up 83.1% +6.3% vs +12.9% a year | RIGL trailed the S&P 500 by 47.1 percentage points Trailed |
| 10Y | RIGL: up 30.2% S&P 500: up 319.6% +2.7% vs +15.4% a year | RIGL trailed the S&P 500 by 289.4 percentage points Trailed |
$10,000 invested in RIGL 10 years ago (Oct 14, 2016) would be worth about $13,023 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
RIGL beat the S&P 500 in 4 of 7 periods.
| Period | RIGL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RIGL: up 3.3% S&P 500: up 1.2% | RIGL beat the S&P 500 by 2.1 percentage points Beat |
| 3M | RIGL: up 10.3% S&P 500: up 1.7% | RIGL beat the S&P 500 by 8.6 percentage points Beat |
| YTD | RIGL: up 7.3% S&P 500: up 11.9% | RIGL trailed the S&P 500 by 4.6 percentage points Trailed |
| 1Y | RIGL: up 63.5% S&P 500: up 15.5% | RIGL beat the S&P 500 by 48.0 percentage points Beat |
| Long term | ||
| 3Y | RIGL: up 375.6% S&P 500: up 75.0% +68.2% vs +20.5% a year | RIGL beat the S&P 500 by 300.6 percentage points Beat |
| 5Y | RIGL: up 36.0% S&P 500: up 71.2% +6.3% vs +11.4% a year | RIGL trailed the S&P 500 by 35.2 percentage points Trailed |
| 10Y | RIGL: up 30.2% S&P 500: up 258.1% +2.7% vs +13.6% a year | RIGL trailed the S&P 500 by 227.9 percentage points Trailed |
$10,000 invested in RIGL 10 years ago (Oct 14, 2016) would be worth about $13,023 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$1,068.30
Closing high on . Now 95.7% below that record.
Split-adjusted daily closes since Nov 29, 2000.
Stock splits
2
Latest: 1-for-10 on . Share counts adjust after each split.
Both splits
- 1-for-10
- 1-for-9
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $276.79Mup 3.3%
- Net income
- $321.91Mup 229.1%
- Diluted EPS
- $16.88up 211.4%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $55.31M | $12.42M | $0.70 |
| Q4 FY24 (Dec 31, 2024) | $57.60M | $14.34M | $0.81 |
| Q1 FY25 (Mar 31, 2025) | $53.33M | $11.45M | $0.63 |
| Q2 FY25 (Jun 30, 2025) | $101.69M | $59.61M | $3.28 |
| Q3 FY25 (Sep 30, 2025) | $69.46M | $27.90M | $1.46 |
| Q4 FY25 (Dec 31, 2025) | $69.80M | $268.07M | $14.10 |
| Q1 FY26 (Mar 31, 2026) | $58.82M | $8.65M | $0.44 |
| Q2 FY26 (Jun 30, 2026) | $78.70M | $17.29M | $0.88 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $149.24M | −$17.91M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $120.24M | −$58.57M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $116.88M | −$25.09M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $179.28M | $17.49M | $0.99 |
| FY25 (Dec 31, 2025) | $294.28M | $367.02M | $19.48 |
Margins
- Gross 91.4%
- Operating 31.5%
- Net 116.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $9.04MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$79.39MLast 12 months
- Capital spending$70.35MLast 12 months
- 3.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $5.13MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $95.33MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$39.95MAs of Jun 30, 2026
- Net cash$55.38MAs of Jun 30, 2026
- 1.94As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.09As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 96.5%Last 12 months
Over the last 12 months, Rigel Pharmaceuticals’s net income was 96.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 72.3%Last 12 months
Over the last 12 months, Rigel Pharmaceuticals’s net income was 72.3% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. As of December 31, 2011, product development programs included fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) with its partner AstraZeneca (AZ); R343, an inhaled SYK inhibitor for asthma and R333, a topical janus kinase (JAK)/SYK inhibitor for discoid lupusboth of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye. In December 2012, the Company initiated a Phase 1 clinical study of R348, a topical ophthalmic JAK/SYK inhibitor, as a potential therapeutic for chronic dry eye.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RIGL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RIGL stock FAQ
What is RIGL stock’s price today?
Rigel Pharmaceuticals (RIGL) traded at $45.97 at the close on , down $1.28 (2.71%) from the previous close of $47.25. Over the past 52 weeks it has traded between $24.95 and $52.24.
If you invested $1,000 in RIGL 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RIGL on would be worth about $1,302 at the close on , a total return of +30.2%. The same $1,000 would be worth $1,360 if invested five years ago, $1,635 if invested one year ago, and $396 if invested 20 years ago. Past performance doesn’t predict future returns.
What is RIGL’s P/E ratio?
RIGL trades at 2.7 times its diluted earnings over the four quarters to ($16.88 per share), at the close. (How the P/E ratio works.)
How much revenue does Rigel Pharmaceuticals make?
Rigel Pharmaceuticals reported $276.8 million of revenue over the four quarters to , up 3.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $78.7 million, down 22.6% from a year earlier.
Is Rigel Pharmaceuticals profitable?
Yes. Rigel Pharmaceuticals earned $321.9 million of net income over the four quarters to , a net margin of 116.3%, and its operating margin was 31.5% (what margins tell you).
What are RIGL’s earnings per share?
RIGL’s diluted earnings per share were $16.88 over the four quarters to , compared with $5.42 in the twelve months before. The latest quarter (Q2 FY26) brought $0.88 per share, against $3.28 a year earlier (how EPS works).
Does RIGL pay a dividend?
Rigel Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is RIGL’s 52-week high and low?
Over the past 52 weeks RIGL has traded as low as $24.95 and as high as $52.24. At $45.97 at the close on , it is 12.0% below that high and 84.2% above the low.
What is RIGL’s all-time high?
RIGL’s highest closing price was $1,068.30 on , adjusted for stock splits. At $45.97 at the close on , it is 95.7% below that record.
Has RIGL stock ever split?
Yes, twice: 1-for-9 on ; 1-for-10 on .
How has RIGL stock performed?
Including dividends and measured to the close on , RIGL has returned +7.3% so far this year and +63.5% over the past year, and +36.0% over five years (+6.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Rigel Pharmaceuticals in?
Rigel Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does RIGL trade on?
Rigel Pharmaceuticals trades on the Nasdaq under the ticker symbol RIGL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.